Although eosinophilia (eosinophil count >0.60 x 10(9)/l), is a prothrombotic condition, little is known on the association between eosinophil count in blood and first-line coagulations tests, including fibrinogen, activated partial thromboplastin time (APTT), prothrombin time (PT) and platelet count. Cumulative results of APTT, PT, fibrinogen, platelet and eosinophil counts were retrieved from 6,944 outpatients >15 years old referred to our laboratory for routine blood testing over the previous 3 years. The median value and the percentage of patients with abnormal values of platelet count and fibrinogen but not APTT and PT, were significantly higher in patients with eosinophilia. This epidemiological association in a large subset of patients provides an additional potential mechanism to explain the link between eosinophilia and thrombosis and is consistent with the hypothesis that platelet count and fibrinogen might be worthwhile assessing in the presence of an abnormal eosinophil count.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11239-008-0247-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brensocatib in patients with bronchiectasis: subgroup analyses from the WILLOW trial.
ERJ Open Res
January 2025
University of Connecticut School of Medicine, Farmington, CT, USA.
Introduction: Bronchiectasis is a chronic inflammatory airway disease. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), reduces pulmonary inflammation by preventing the activation of neutrophil serine proteases. In the phase II WILLOW trial, brensocatib prolonged time to first exacerbation in patients with bronchiectasis.
View Article and Find Full Text PDFAssociation of LPCAT1-rs8352 genetic variant with susceptibility and severity of pediatric bronchial asthma: a case-control study.
BMC Pediatr
January 2025
Department of Pediatrics, Faculty of Medicine, Assiut University, Egypt, 71515, Assiut, Egypt.
Background: This study aimed to investigate the possible association of LPCAT1-rs8352 genetic variant (single nucleotide change C to G) with the onset and severity of pediatric asthma. Additionally, the study examined the influence of LPCAT1-rs8352 genotypes on asthma-related biomarkers including blood eosinophils count (BEC), eosinophil cationic protein (ECP), high-sensitivity C-reactive protein (hs-CRP), and immunoglobulin E (IgE) and on lung function [forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC)].
Patients And Methods: The study included ninety-six participant grouped into two groups: G1 (46 asthmatics) and G2 (50 healthy controls).
Introduction: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe hypersensitivity reaction rarely documented in patients with multiple myeloma (MM).
Methods: In our retrospective study of 108 newly diagnosed MM (NDMM) patients from January 2021 to October 2023, we identified four cases of DRESS. The clinical characteristics such as clinical manifestations, laboratory results, treatment and outcome were analyzed.
Myocarditis with neurological and dermatological involvement in idiopathic Hypereosinophilic syndrome: Case report.
Radiol Case Rep
March 2025
Laboratory of Epidemiology, Clinical Research and Public Health, Faculty of Medicine and Pharmacy, Oujda, Morocco.
Eosinophilic myocarditis (EM), irrespective of its unique etiology, is marked by varying extents of eosinophil infiltration, frequently accompanied by peripheral eosinophilia. In some instances, the etiology remains undetermined, thus classified as idiopathic hypereosinophilic syndrome. The clinical manifestations are highly variable, ranging from mild or asymptomatic presentations to acute fulminant myocarditis or chronic restrictive cardiomyopathy.
View Article and Find Full Text PDFIntroduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!